Arnulf Stenzl, MD
Enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) demonstrated significantly improved radiographic progression-free survival (rPFS) versus placebo plus ADT, regardless of baseline prostate-specific antigen (PSA) levels, according to expanded findings from the ARCHES study.1
The PSA finding is important finding because baseline levels are considered a strong prognostic indicator for clinical outcomes in men with mHSPC following ADT,2
Arnulf Stenzl, MD, said in presenting the data during the American Urological Association 2019 Annual Meeting.1
The results suggest the limitations of baseline PSA as a predictive factor among patients who have received prior ADT, Stenzl and colleagues said in their conference abstract.
At the same time, strong improvements in the PSA-related endpoints of time to PSA progression, PSA reduction from baseline, and PSA undetectable rate were also observed with enzalutamide therapy, the abstract noted (Table
... to read the full story